PROVEN SAFETY AND TOLERABILITY PROFILE1

Most adverse events reported with UBRELVY were mild or moderate with frequencies comparable to placebo.

In an open-label 52-week study…

2.5% of patients discontinued treatment due to an adverse event, however, no single event led to discontinuation in more than 2 patients.

The incidence of serious adverse events with UBRELVY was low and comparable to usual care (2.2% UBRELVY 50 mg; 2.9% UBRELVY 100 mg; 4.1% usual care).

In the open-label 52-week study, 21,454 migraines were treated with UBRELVY.1

PROVEN SAFETY AND TOLERABILITY PROFILE1

Most adverse events reported with UBRELVY were mild or moderate with frequencies comparable to placebo.

In an open-label 52-week study…

2.5% of patients discontinued treatment due to an adverse event, however, no single event led to discontinuation in more than 2 patients.

The incidence of serious adverse events with UBRELVY was low and comparable to usual care (2.2% UBRELVY 50 mg; 2.9% UBRELVY 100 mg; 4.1% usual care).

In the open-label 52-week study, 21,454 migraines were treated with UBRELVY.1

PROVEN SAFETY AND TOLERABILITY PROFILE1

Most adverse events reported with UBRELVY were mild or moderate with frequencies comparable to placebo.

In an open-label 52-week
study…

2.5% of patients discontinued treatment due to an adverse event, however, no single event led to discontinuation in more than 2 patients.

The incidence of serious adverse events with UBRELVY was low and comparable to usual care (2.2% UBRELVY 50 mg; 2.9% UBRELVY 100 mg; 4.1% usual care).

In the open-label 52-week study, 21,454 migraines were treated with UBRELVY.1

SAFETY INFORMATION

Click here for additional safety information and for a link to the Product Monograph discussing:

Contraindications with concomitant use of strong CYP3A4 inhibitors.

Relevant warnings and precautions regarding driving and operating machinery, hypersensitivity reactions, may reduce effectiveness of oral contraceptives, use in pregnant or breast-feeding women and dose selection in geriatric patients.

Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

 

FOR MORE INFORMATION

For any questions related to UBRELVY, you can contact AbbVie Medical Information at 1-844-241-5011

SAFETY INFORMATION

Click here for additional safety information and for a link to the Product Monograph discussing:

Contraindications with concomitant use of strong CYP3A4 inhibitors.

Relevant warnings and precautions regarding driving and operating machinery, hypersensitivity reactions, may reduce effectiveness of oral contraceptives, use in pregnant or breast-feeding women and dose selection in geriatric patients.

Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

 

FOR MORE INFORMATION

For any questions related to UBRELVY, you can contact AbbVie Medical Information at 1-844-241-5011

SAFETY INFORMATION

Click here for additional safety information and for a link to the Product Monograph discussing:

Contraindications with concomitant use of strong CYP3A4 inhibitors.

Relevant warnings and precautions regarding driving and operating machinery, hypersensitivity reactions, may reduce effectiveness of oral contraceptives, use in pregnant or breast-feeding women and dose selection in geriatric patients.

Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

 

FOR MORE INFORMATION

For any questions related to UBRELVY, you can contact AbbVie Medical Information at
1-844-241-5011

*Safety evaluated in 3664 patients who received at least one dose of UBRELVY. In the two randomized, double-blind, placebo-controlled, phase 3 trials in adult patients with migraine (ACHIEVE I and ACHIEVE II), a total of 1439 patients received UBRELVY 50 mg or 100 mg.

Long-term safety assessed in 813 patients, dosing intermittently for up to 1 year in an open-label extension study. Patients were permitted to treat up to 8 migraines per month with UBRELVY. A total of 421 patients were exposed to 50 mg or 100 mg of UBRELVY for at least 6 months, and 364 patients were exposed to these doses for at least 1 year, all of whom treated at least 2 migraine attacks per month, on average. In this study 21,454 migraines were treated with UBRELVY.

Usual care patients were instructed to treat their migraine with the medication(s) that they routinely take to relieve a migraine attack.

Reference:

1. UBRELVY (ubrogepant) Product Monograph. AbbVie Corporation. 

UBRELVY and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation. 

© 2024 AbbVie. All rights reserved. 

CA-UBR-230004A / JN24  

UBRELVY and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation. 

© 2024 AbbVie. All rights reserved. 

CA-UBR-230004A / JN24